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LATELET RESPONSES appear to be regulated by the extent to which proteins are phosphorylated on seryl, threonyl, and tyrosyl residues. Such phosphorylation events reflect the relative activities of protein kinases (PKs) and phosphoprotein phosphatases. For the most part, enzymes that phosphorylate/dephosphorylate proteins on tyrosyl residues constitute classes of enzymes distinct from protein seryVthreony1 kinases and phosphatases.' Many seryVthreonyl PKs have been classified with respect to their regulation by specific effectors such as cyclic adenosine monophosphate (CAMP), cyclic guanosine monophosphate (cGMP), Ca2+, and diacylglycerol. In platelets, several messengerdependent PK activities have been characterized, and their involvement in platelet reactions have been well studied. Activation of protein kinase C (PKC) and myosin light chain kinase, classes of enzymes that are regulated by phospholipids and Ca'+, respectively, occur in response to the activation of receptors of various positive effectors such as thrombin, collagen, adenosine diphosphate (ADP), and thromboxanes.' In addition, the antagonistic effects of negative effectors such as prostaglandins Iz (PGIz), PGEl, and nitric oxide are mediated by the action of CAMP-and cGMPdependent PKs, re~pectively.~.~ Although several studies have suggested that two isoforms of the CAMP-PK, types I and 11, and four isoforms of PKC (a, p, 7 , l , ) , are present in platelets, specific roles for each have not yet been des~r i b e d .~.~ Several lines of evidence suggest that other serine/threonine PKs are present in platelets. First, in vitro kinase assays performed with blotted proteins have resolved 14 platelet serine/threonine PKs. 8 The autophosphorylating activities of 10 of these putative kinases are increased in thrombin-stimulated platelets. It has been well established that there are a large number of messenger-independent PKs (including mitogen-activated protein [MAP] kinases, casein kinases and a number of histone kinases)'"' that play an important role in the transmission of regulatory signals. Although the identity of the 14 platelet serine/threonine kinases was not determined,' 3 apparently have the ability to phosphorylate histones. Consistent with this, it has been shown that platelets contain various histone kinases, including the isozymes of PKC discussed a b~v e~.~ and members of cyclin-dependent PKs.'*.'~ Finally, incubation of platelets with various growth factors, eg, insulin, leads to the stimulation of messengerindependent protein serinekhreonine kinase^.'^,'^ Phosphorylation events are not necessarily controlled by messenger-dependent PKs. Several phosphorylation events within the platelet appear to be controlled through the regulation of protein phosphatase^.'^^'^ Inhibition of types 1 and 2A protein phosphatase results in desensitization of human platelets to agonists such as thrombin.17"' This desensitization occurs concomitantly with a burst of specific phosphorylation events. In studies to characterize messenger-independent PKs responsible for these phosphorylations, we found that platelets contain a significant amount of casein kinase 2 (CKII). The present work shows that CKII is constitutively active in human platelets, suggesting that its effects are tightly modulated by phosphoprotein phosphatases. Isolation of platelets. Human blood (10 parts) was drawn into acid/citrate/dextrose (1 part). Platelet-rich plasma was obtained after centrifugation at 210g for 10 minutes at 21°C. After the addition of PGE, (0.4 pmoVL) and apyrases (12.5 mU/mL) platelets were removed by centrifugation at 1,lOOg for 15 minutes at 21°C. Platelets were resuspended in a modified Tyrode's buffer, pH 6.4, containing 5 mmol/L HEPES, 140 mmol/L NaC1, 1 mmoW MgClz, 2 mmoll L KCl, 5.5 mmol/L glucose, 12 mmol/L NaHC03, 0.2% (wt/vol) bovine serum albumin, 0.2 pmol/L PGE, , and apyrases (6 mUlmL), recentrifuged at 1,100g, and suspended at the indicated concentrations in a buffer containing 10 mmoVL HEPES, pH 7.4, 2 mmoUL KCl, 140 mmol/L NaCl, 1 mmol/L MgClz, and 5.5 mmol/L glucose.
MATERIALS AND METHODS

Materials
Platelet numbers were determined using a PS5 Blood Cell Counter (Diagnostic Technologies, Hauppauge, NY).
Separation of platelet PKs. Platelet suspensions (2 to 5 X IO"/ mL) were incubated with either buffer or thrombin (1 UlmL) at 21°C for periods up to 5 minutes. Reactions were quenched by addition of an equal volume of 2X lysis buffer (50 mmol/L Tris-HCI, pH 7.5.5 mmol/L NaEDTA, 2 mmoVL sodium orthovanadate [Na,VO,], 1 mmol/L sodium molybdate, 10 mmol/L sodium fluoride, 1 mmoll L benzamidine, 20 pg/mL leupeptin, 10 pg/mL aprotinin, 10 pgl mL ovomucoid, 10 pg/mL pepstatin A, 1% Nonidet P-40, 12.5 m o l / L P-glycerophosphate, 1 mmol/L dithiothreitol, 2.5 UlmL hirudin). The platelets were further disrupted by sonication at 0°C. The homogenate was centrifuged at 100,OOOg for 30 minutes, and the supernatant (1 to 3 mg protein) was loaded onto a MONO Q column (HR5\5, 1 mL) equilibrated with 20 mL of wash buffer (5 mmol/L Mops, pH 7.2, 5 mmol/L EGTA, I mmol/L dithiothreitol, 0.5 mmol/L sodium fluoride, 12.5 mmol/L ,&glycerophosphate, 1 mmol/L Na3V04, 1 mmol/L sodium molybdate). Samples were eluted using a flow rate of 0.25 mL/min with a 20 mL linear gradient of sodium chloride (0 to 0.5 mmol/L). Fractions (0.5 mL) were collected, and PK activity was measured.
PK assays. The assays were all based on the transfer of '*P from [y3zP]ATP to specific substrates. For CKII and myelin basic protein (MBP) assays, the assay mixtures (30 pL) contained 10 to 15 L Na3V04. The reactions were initiated by addition of the CKII peptide substrate RRRDDDSDDD (0.1 mmoVL) or MBP (0.5 mg/ mL) and, after incubation at 30°C. quenched by the addition of 15 pL glacial acetic acid. The amount of phosphorylated substrate was determined using phosphocellulose paper, as previously described.24 To determine the amount of active MAP kinase activity present in platelets, column fractions were assayed as described for MBP kinase assays; however, a synthetic peptide substrate (APRTPGGRR) more selective for MAP kinasez5 was used. For protein tyrosine kinase assays, the reaction mixtures (30 pL) contained 20 mmol/L Imidazole, pH 7.2, 100 pmol/L [32P]ATP (1 cpm/fmol), 12 mmol/ L Mg Acetate, 2 mmol/L MnCl,, and 200 pmol/L dithiothreitol. The reactions were initiated by addition of 2 mmol/L RR-src peptide (RRLIEDAEYAARG) and were incubated at 30°C. The incorporation of 3zP into the substrate was determined using phosphocellulose paper.
Immunoelectron microscopy. Platelet suspensions (2 X 1 O'/mL) were incubated at 37°C with and without thrombin (0.2 UlmL) for 15 seconds or 2 minutes. Reactions were stopped by addition of equal volumes of 0.3% glutaraldehyde containing 1% sucrose. The fixed preparation was dehydrated, then infiltrated and embedded with LR White resin, as described by the manufacturer (London Resin Company, Hampshire, UK). Thin sections were prepared and incubated for 2 hours at 21°C with or without primary antibody (anti-n or a' antibody, nonimmune serum, or antiopsin antibody; 1:lOOO in phosphate-buffered saline containing 1% goat serum) followed by incubation with goat-antirabbit antiserum conjugated to 20-nm gold particles (1:lOO). Electron microscopy was performed using a Hatachi electron microscope, model 7000 (New York Medical College, Valhalla, NY).
Immunoprecipitation, sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and Western analysis. Column fractions were either solubilized directly with SDS gel buffer (30 mmoV L Tris-HC1, pH 6.8, 10% glycerol, 5% SDS, 0.1% bromophenol blue) or incubated with peptide antibodies, which were generated against the a-, a'-, or ,%subunits of CKII?' for 16 hours at 4°C and subsequently incubated with protein A-Sepharose for 1 hour at 4°C. The immunoprecipitates were washed 3 times with RIPA (50 mmoU L Tris-HC1, pH 7.5, 1% Nonidet P-40, 0.5% deoxycholate, 0.1% SDS, 20 pg/mL leupeptin, 10 pg/mL aprotinin, 1 mmol/L benzamidine, 2 mmol/L dithiothreitol, 10 mmol/L sodium fluoride, 2 mmol/ L Na3V04, 1 mmol/L sodium molybdate), and solubilized with SDS sample buffer. Proteins were separated by SDS-PAGE using 10% gels. The proteins were immediately transferred electrophoretically onto nitrocellulose and incubated successively with (1) 5% nonfat milk in Tween containing Tris-buffered saline (TIBS; 20 mmol/L Tris-HC1, pH 7.5, 0.5 mol/L NaCI, 0.05% Tween 20), (2) primary antibody solutions (1:1,000) containing 3% nonfat milk in TTBS, and (3) HRP-conjugated goat antirabbit IgG (1:2,500). The second antibody was detected using Amersham's ECL system.
RESULTS
Identibing CKII in human platelets and effect of activation on activity. Results from our laboratory suggest that messenger-independent PKs may modulate platelet responses.'3 As a first step toward identifying such enzymes, extracts from resting and thrombin-activated platelets were prepared and proteins fractionated by MONO Q FPLC chromatography. Column fractions were assayed for distinct subfamilies of PKs classified on the basis on (1) their specificity for tyrosyl or seryVthreony1 residues and (2) their usage of acidic and basic substrates26 : Fractions were assayed for PK activities using MBP, the RR-src peptide as a substrate for protein tyrosine kinases, and a synthetic substrate for CKII.
Three major peaks of kinase activity were found. Peak I eluted at NaCl concentrations of 210 mmol/L and was detected in both preparations of lysates using RR-src peptide to measure protein tyrosine kinase activity (Fig 1A) . Peak I1 eluted at 250 mmol/L NaCl and an increase in activity was detected with MBP as substrate in lysates prepared from platelets activated with either thrombin (1 U/mL) or the tethered-receptor peptide (10 pmol/L; Fig 1B) . fraction, 0.5 mL 98% of this kinase activity was inhibited by addition of 0.1 pmol/L staurosporin to the assay. Surprisingly, peak I1 kinase activity was inhibited by only 30% to 50% when the PKC inhibitor peptide RFARKGALRQKNV (10 pmol/L) was added to the column fractions (n = 2), suggesting that this activity was attributed to more than a single PK. MBP can be phosphorylated by many PKs in vitro including MAP kinases.*' To determine whether MAP kinases were present in peak 11, assays were performed with the synthetic peptide APPTPGGRR that is a more selective substrate for MAP kinase than MBP." Although we used homogenization and fractionation procedures that preserve MAP kinase activation in various cell types?"." this peptide was not phosphorylated when fractions 31 through 45 were assayed. A third PK activity was detected using the synthetic peptide RRRDDDSDDD (DSD peptide), a CKII substrate ( Fig  1C) . Peak 111 eluted at a NaCl concentration of 400 mmol/ L, consistent with the elution profile of authentic CKII?' To confirm the presence of CKII, column fractions were analyzed by Western blotting with antipeptide antibodies raised against a-and a'-subunits of the enzyme.2' Both antibodies recognized subunits in the peak fractions, indicating that both a'-( Fig 1D) and a-(data not shown) subunits are present in human platelets. Similarly, antipeptide antibodies raised against the &subunit reacted with a protein whose molecular weight corresponds to that of the &subunit of CKII (data not shown).
To investigate whether thrombin treatment of platelets affects CKII activity, platelets were stirred with 1 U/mL thrombin for 2 minutes at 21°C and were lysed, and proteins fractionated by MONO Q FPLC chromatography (Fig 1C) . Under these conditions, maximal platelet secretions and aggregation occurred as determined with a Chronolog Lumi Aggregometer (Haverton, PA). However, CKII activity and levels did not change as assessed by DSD peptide phosphorylation ( Fig 1C) and Western analysis (data not shown), respectively. In addition, there was no increase in CKII activity 15 seconds after thrombin addition. This suggests that the enzyme was not transiently activated. In a recent report, Haimovich and coworkers" indicated that the induction of certain phosphorylation events is dependent on the interaction of platelets with various matrixes. We found that the spreading of platelets on fibrinogen-coated dishes did not affect CKII activity (data not shown).
Localization of CKII in resting and activated platelets. Results from a recent study suggest that a CKII-like activity is released from thrombin-stimulated platelets.'2 To evaluate the possibility that CKII is secreted, we analyzed the extra- For personal use only. on October 26, 2017. by guest www.bloodjournal.org From cellular media from activated platelets for CKII. Two lines of evidence support the notion that the enzyme is not secreted as a result of activation. First, no detectable activity was found in the secreted fraction that was collected and fractionated by MONO Q P L C . In contrast, 1 0 0 % of the CKII activity was found to be associated with the platelet pellet (data not shown). These studies suggest that the kinase was not released by agonist treatment. This was confirmed in studies that evaluated the distribution of CKII in resting and activated platelets by electron microscopy (Fig 2) and immunogold labeling using antibodies raised against the aand a'-subunits (Fig 2, panels B through D) . Thin sections of platelets were incubated with CKII antiserum followed by antirabbit IgG coupled to colloidal gold. Electron microscopy showed that immunoreactive a-and a'-subunits were distributed throughout resting platelets (Fig 2, panel B and data not shown, respectively). After stimulation with thrombin, gold particles were still observed throughout the platelet even after an incubation period of 2 minutes at 37°C (Fig 2,  panels C and D) . The apparent amount of gold particles observed in resting and activated platelets was equivalent, suggesting that CKII was not being secreted after thrombin treatment. Immunogold labeling was not observed in sections treated with no primary antibody (data not shown), nonimmune rabbit serum (Fig 2, panel A) , or antisera that specifically recognized redgreen cones in retina (data not shown).
CKII subunit composition in human platelets. CKII exits as a tetrameric enzyme with an a d 2 , or aa',B2 composition." To determine its composition in platelets, CKII was eluted from the MONO Q column and immunoprecipitated using antiserum that specifically recognized each of the subunits. The immunoprecipitates were then subjected to Westem analysis using anti-a-and a'-antiserum. Antibodies directed toward each of the subunits immunoprecipitated a form of CKII that contained a complex of a-, a'-, and Psubunits (Fig 3) .
DISCUSSION
It has been established that treatment with agonists and antagonists induces changes in phosphorylation of a number of platelet proteins.' Initial studies showed a correlation between serylhhreonyl phosphorylation events with platelet responses such as secretion and aggregation." Similarly, evidence shows a relationship between tyrosyl phosphorylation reactions and platelet response^.."^.'^"^ The list of protein kinases and phosphatases identified in platelets is growing. With respect to the latter class of enzymes, platelets contain protein serylhhreonyl phosphatase types 1,'7.'7 2A,'7.'7 and 2B,3X.3y and protein tyrosyl phosphatase activity(ies) (lanes l), a'-(lanes 2). or p-(lanes 3) antisera. The immunoprecipitates and nonprecipitated column fraction (lanes 4) were subjected to Western analysis using an antibody against either the a'-(A) or a-(B) subunit of CKII. These antibodies recognized a' (molecular  weight, 40 kD) and a (molecular weight, 45 kD) , respectively, as indicated by the arrow heads. Prestained molecular weight markers (expressed as kilodaltons) shown are ovalbumin (49,500) and carbonic anhydrase (32.500). The heavily stained band indicated by the asterisk (*) represents heavy chains of IgG.
whose identity(ies) has yet to be characterized. Similarly, little is known about the identity of PKs in platelets. From the work of Ferrell and Martin,R it is clear that the identity of only a limited number of protein serylhhreonyl kinases found in platelets is known. Although the majority of the PK activities measured in their study was increased in thrombintreated cells; some appeared to be nonresponsive. Similarly, several protein tyrosine kinases, eg, fyn, yes, hck, and lyn, have been identified in platelets, but agonist-induced changes in their activities have not yet been shown?' The simplest interpretation of these observations is that the phosphorylation events catalyzed by putative, constitutively active PKs are tightly regulated by protein phosphatase activities. In support of this possibility are data presented in previous studies.".I6 Selective inhibitors of protein seryllthreonyl phosphatases cause increases in specific protein phosphorylations, events that correlate with the desensitization of platelets to several agonists. Alternatively, protein phosphorylation events may depend on the redistribution or targeting of PKs (or phosphoprotein phosphatase^)^' to subcellular compartments. Subcellular redistribution of type I1 PKA has been shown to occur after FSH treatment of granulosa cells? Similarly, in neutrophils, it has been recently shown that, on fMLP stimulation, &MP-dependent PK colocalizes with substrates." In addition, thrombin treatment of platelets causes the redistribution of pp60"" and other related protein tyrosine kinases from the soluble fraction to the cytoskelet on: ' This translocation, in turn, correlates with the phosphorylation of several proteins on tyrosyl residues. Together, these observations support the concept that targeting specific PKs to substrates may control phosphorylation processes. Lastly, changes in the activity of specific PKs may not be found because of technical constraints. Until recently, no changes in protein tyrosine kinase activities were detected after agonist stimulation of platelets. On reexamination of the effect of agonists on tyrosine kinase activities, several laboratories have found transient increases in both ~~6 0 "~ and p7Tyk4' in platelets. In the present study, however, transient increases in CKII activity were not detected in platelets. There has been controversy over whether CKII is constitutively active in cells.'' There are indications from a number of studies"' that the distribution of CKII within cells changes during different growth states or at different stages in the cell cycle. These observations suggest that increased phosphorylation of particular substrates by CKII may result from its redistribution rather than from apparent changes in its catalytic activity. Our data suggest that CKII is constitutively active in human platelets. Because different treatments of platelets may engage different cascade events, it remains possible that CKII activity is regulated by other soluble agonists, or antagonists, or by events such as adhesion or aggregation. In the studies described here, no significant changes were found in platelets that were allowed to undergo aggregation or to adhere to fibrinogen. Other soluble agonists were not directly used in these studies. However, in that ADP is released and has a positive effect on adhered platelets,'' our studies further rule out an effect of ADP on CKII activity. Based on the present results, it can be speculated that CKII effects are regulated either by protein phosphatases or by accessibility to substrates. This appears analogous to protein tyrosine kinases in platelets. Whereas tyrosine phosphorylation increases after thrmbin treatment of platelets, changes in the activity of many tyrosine kinases in platelets have not been shown. We have also found that overall tyrosine kinase activity, as measured with exogenous substrates, is not changed in platelets stimulated for short periods (eg, 15 seconds) or for 2 minutes. In contrast, histone kinase activity increases under these conditions.
The identity of most of the renaturable kinases detected by Ferrell and Martin8 is not known. However, they do point out that the renaturation approach may not be applicable for the detection of many PKs. Renaturable kinases that have molecular masses similar to those of a-(45 kD) and a'-(40 kD) subunits of CKII were detected. However, because catalytic subunits of CKII are only autophosphorylated under specialized it is not yet clear whether these renaturable kinases are the catalytic subunits of CKII.
Additional findings show that human platelets contain all three known subunits (a, a', and p) of CKII and that the enzyme is distributed throughout the platelet. A great deal of evidence suggests that CKII has an important role in regulating nuclear events in other cells." Its detection in our study indicates that CKII must also have a role in nonnuclear events, because platelets do not have nuclei. Other investigator~~~.'' have reported the presence of CKII in other nonnucleated cells including reticulocytes and erythrocytes. Although the precise location of CKII in platelets is not known, the kinase does not appear to be localized in the granules. Recently, Kalafatis et al'2 examined a PK activity that was secreted after exposure of platelets to IO U/mL thrombin.
Under these conditions, they found released CKII-like activity. However, we find that thrombin concentrations up to 1 U/ mL do not cause the release of authentic CKII from platelets. Whether the enzyme redistributes after activation still needs to be addressed. 35. Golden A, Brugge JS: Thrombin-treatment induces rapid changes in tyrosine phosphorylation in platelets. Proc Natl Acad Sci USA 86: 901, 1989 36. Nakamura S, Uamamura H: Thrombin and collagen induce rapid phosphorylation of a common set of cellular proteins on tyrosine in human platelets. J Biol Chem 264: 7089, 1989 37. Erdodi F, Csortos C, Sparks L, Muranyi A, Gergely P: Purification and characterization of three distinct types of protein phosphatase catalytic subunits in bovine platelets. Arch Biochem Biophys 298: 682, 1992 For personal use only. on October 26, 2017. by guest www.bloodjournal.org From
